Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fenaux

Showing results (261-270 of 320) with videos related to

Pageof 32
Sort By:
Molecular and Cellular Biology|January 26, 2011
New role for granulocyte colony-stimulating factor-induced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor α recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiationB Cassinat, F Zassadowski, C Ferry, et al.
Blood|October 7, 2000
High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21C Preudhomme, D Warot-Loze, C Roumier, et al.
Bone Marrow Transplantation|April 16, 2013
Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDSM Robin, R Porcher, L Adès, et al.
Blood|November 26, 1999
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemiaE Archimbaud, O G Ottmann, J A Yin, et al.
International Journal of Laboratory Hematology|July 31, 2010
Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT-X) determined by the Sysmex XE-2100™G Le Roux, A Vlad, V Eclache, et al.
Blood|March 15, 1997
International scoring system for evaluating prognosis in myelodysplastic syndromesP Greenberg, C Cox, M M LeBeau, et al.
Bone Marrow Transplantation|September 23, 2014
Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AMLM Sébert, R Porcher, M Robin, et al.
Leukemia|February 24, 2001
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromesE Solary, L Mannone, D Moreau, et al.
Leukemia|April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson, O Kosmider, T Cluzeau, et al.
Bone Marrow Transplantation|March 20, 2012
Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AMLM A Hospital, X Thomas, S Castaigne, et al.
Pageof 32

Showing results (261-270 of 320) with videos related to

Sort By:
Pageof 32
Molecular and Cellular Biology|January 26, 2011
New role for granulocyte colony-stimulating factor-induced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor α recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiationB Cassinat, F Zassadowski, C Ferry, et al.
Blood|October 7, 2000
High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21C Preudhomme, D Warot-Loze, C Roumier, et al.
Bone Marrow Transplantation|April 16, 2013
Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDSM Robin, R Porcher, L Adès, et al.
Blood|November 26, 1999
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemiaE Archimbaud, O G Ottmann, J A Yin, et al.
International Journal of Laboratory Hematology|July 31, 2010
Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT-X) determined by the Sysmex XE-2100™G Le Roux, A Vlad, V Eclache, et al.
Blood|March 15, 1997
International scoring system for evaluating prognosis in myelodysplastic syndromesP Greenberg, C Cox, M M LeBeau, et al.
Bone Marrow Transplantation|September 23, 2014
Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AMLM Sébert, R Porcher, M Robin, et al.
Leukemia|February 24, 2001
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromesE Solary, L Mannone, D Moreau, et al.
Leukemia|April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson, O Kosmider, T Cluzeau, et al.
Bone Marrow Transplantation|March 20, 2012
Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AMLM A Hospital, X Thomas, S Castaigne, et al.
Pageof 32